+Compare
INCR
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
56.05M

INCR Intercure Ltd Forecast, Technical & Fundamental Analysis

a provider of outsourced clinical development and commercialization services to biopharmaceutical companies

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for INCR with price predictions
07:00 PM EST Dec 04, 2023

INCR's Stochastic Oscillator sits in overbought zone for 1 day

Expect a price pull-back in the near future.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

INCR broke above its upper Bollinger Band on November 15, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INCR entered a downward trend on November 13, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCR's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 01, 2023. You may want to consider a long position or call options on INCR as a result. In of 116 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for INCR just turned positive on November 03, 2023. Looking at past instances where INCR's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

INCR moved above its 50-day moving average on December 04, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INCR advanced for three days, in of 166 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.412) is normal, around the industry mean (47.989). P/E Ratio (10.000) is within average values for comparable stocks, (60.542). INCR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.883). INCR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (0.509) is also within normal values, averaging (65.502).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. INCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.76B. The market cap for tickers in the group ranges from 246 to 82.08B. ZTS holds the highest valuation in this group at 82.08B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 29%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was -4%. INNPF experienced the highest price growth at 6,367%, while CNTRF experienced the biggest fall at -65%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was 46% and the average quarterly volume growth was 64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 68
Price Growth Rating: 53
SMR Rating: 84
Profit Risk Rating: 91
Seasonality Score: 25 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

INCR is expected to report earnings to fall 673.42% to 4 cents per share on April 04

Intercure Ltd INCR Stock Earnings Reports
Q4'21
Est.
$0.05
Q3'23
Missed
by $0.04
Q1'23
Missed
by $0.01
Q4'22
Est.
$0.05
Q3'22
Est.
$0.08
The last earnings report on November 14 showed earnings per share of 0 cents, missing the estimate of 3 cents. With 48.82K shares outstanding, the current market capitalization sits at 56.05M.
A.I. Advisor
published General Information

General Information

a provider of outsourced clinical development and commercialization services to biopharmaceutical companies

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Servicestothe Health Industry
Address
85 Medinat ha-Yehudim Street
Phone
+972 774605012
Employees
370
Web
https://www.intercure.co
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RWEOY43.250.25
+0.58%
RWE AG
MTSI84.91-0.19
-0.22%
MACOM Technology Solutions Holdings
SAFE21.95-0.16
-0.72%
Safehold
AMSWA10.16-0.11
-1.07%
American Software
ITRG0.94-0.03
-3.22%
Integra Resources Corp

INCR and

Correlation & Price change

A.I.dvisor tells us that INCR and TLRY have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and TLRY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
-1.17%
TLRY - INCR
27%
Poorly correlated
-9.71%
SNDL - INCR
25%
Poorly correlated
-5.23%
OGI - INCR
25%
Poorly correlated
-5.90%
TEVA - INCR
24%
Poorly correlated
+0.30%
DVAX - INCR
23%
Poorly correlated
-1.22%
More

Groups containing INCR

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
-1.17%
health
(undefined stocks)
16%
Poorly correlated
-1.39%
biopharmaceuticals
(undefined stocks)
15%
Poorly correlated
+0.35%
Pharmaceuticals
(undefined stocks)
3%
Poorly correlated
+0.01%
Pharmaceuticals: Other
(undefined stocks)
3%
Poorly correlated
+0.15%